SCHEMBL808481

SCHEMBL808481

CCC1(N)C=CC=CC1C(=O)O

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 2/20 0.30
GRM2 Q14416 2/20 0.30
GRM3 Q14832 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11528752 0.85
SCHEMBL31070849 0.82 POLA1 (0.30)
SCHEMBL11291066 0.81
Hydrochloric Acid SCHEMBL29024517 0.80 MAPK1 (0.32)
Hydrochloric Acid SCHEMBL29024671 0.80 MAPK1 (0.32)
SCHEMBL1198132 0.78 POLB (0.30)
SCHEMBL18604010 0.77 ALDH1A1 (0.37)
SCHEMBL1194419 0.77
SCHEMBL7569651 0.77
SCHEMBL39621 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481589-B1 ABRASIVE ARTICLES SAINT GOBAIN ABRASIVES INC (US) 2023-08-30 EP claimed
US-11503831-B2 Arthropoda repellent composition SANDERSTROTHMANN GMBH (DE) 2022-11-22 US claimed
CN-113905612-A Arthropod control composition 弗门尼舍有限公司 2022-01-07 CN claimed
EP-3763212-B1 ARTHROPODA REPELLENT COMPOSITION SANDERSTROTHMANN GMBH (DE) 2021-08-18 EP claimed
WO-2021005206-A1 ARTHROPODA REPELLENT COMPOSITION SANDERSTROTHMANN GMBH (DE) 2021-01-14 WO claimed
US-20210007354-A1 ARTHROPODA REPELLENT COMPOSITION SANDERSTROTHMANN GMBH (DE) 2021-01-14 US claimed
EP-3763212-A1 ARTHROPODA REPELLENT COMPOSITION SanderStrothmann GmbH (DE) 2021-01-13 EP claimed
US-20200040108-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA 2020-02-06 US claimed
WO-2020026143-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2020-02-06 WO claimed
EP-3604346-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES Procter & Gamble International Operations SA (CH) 2020-02-05 EP claimed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP claimed
US-12633563-B1 Redox flow battery KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2026-05-19 US disclosed
WO-2024013308-A2 METHOD OF REDUCING NITRO COMPOUNDS THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2024-01-18 WO disclosed
US-11503831-B2 Arthropoda repellent composition SANDERSTROTHMANN GMBH (DE) 2022-11-22 US disclosed
CN-113905612-A Arthropod control composition 弗门尼舍有限公司 2022-01-07 CN disclosed
US-5280067-A Heat curable adhesive MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-01-18 US disclosed
US-5162336-A Disorders of gastrointestinal, central nervous and appetite regulatory systems RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1992-11-10 US disclosed
EP-0491943-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-07-01 EP disclosed
WO-1992000295-A1 TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-01-09 WO disclosed
EP-0385271-A1 Tetrahydroquinolines and method of preparation EASTMAN KODAK COMPANY (US) 1990-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12633563-B1 Redox flow battery SLC9A1, SLC9A2, NOX1 GRM6 2276/4885GRM2 1175/4885GRM3 2489/4885
US-20200040108-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES MGAM, FUT5, FUT6 GRM6 1089/4885GRM2 1992/4885GRM3 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.